DDRGK1 and metabolic dysfunction-associated steatotic liver disease: Furthermore, we demonstrated that ufmylation on UFBP1 K267 was crucial for ameliorating NAFLD phenotypes, including obesity, liver steatosis, hepatic lipogenesis, dyslipidemia, insulin resistance and liver damage.